Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease [Phase 4]
A Phase 4 trial assessed the effects of intraoperative esketamine on postoperative pain and mood in patients with Crohn's disease and depres…
-
CLINICAL_TRIALS withdrawal · 2023-04-03Clinical Trial Update: A Comparative Trial of TMS Approaches to Treating Depression [Phase 4]
Clinical trial in Phase 4 comparing transcranial magnetic stimulation approaches for depression was withdrawn.
-
FDA approval · 2023-04-03FDA Approved: DOXEPIN HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved Novadoz Pharmaceuticals LLC's original application for doxepin hydrochloride (generic). The approval supports the generic produ…
-
FDA approval · 2023-03-31FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for Granules Pharmaceuticals' sertraline hydrochloride generic product, enabling its marketing in th…
-
FDA approval · 2023-03-30FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA granted supplemental approval for a generic venlafaxine hydrochloride product from Aurobindo Pharma Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Understanding How Anaesthesia Affects ECT Outcomes [Phase 3]
Phase 3 clinical trial update examining how anesthesia affects outcomes of electroconvulsive therapy for depression; study completed.
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: CBT Enhanced With Social Cognitive Training [NA]
A completed clinical trial evaluating CBT enhanced with social cognitive training for depression; results posted in 2023.
-
FDA approval · 2023-03-24FDA Approved: FETZIMA — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Fetzima (levomilnacipran hydrochloride) from Allergan, Inc., representing a regulatory action re…
-
FDA approval · 2023-03-23FDA Approved: PAROXETINE — Supplemental Application (Modavar Pharmaceuticals LLC)
FDA approved a supplemental application for generic paroxetine filed by Modavar Pharmaceuticals LLC under ANDA212645.
-
CLINICAL_TRIALS trial_result · 2023-03-22Clinical Trial Update: The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention [Phase 1, Phase 2]
A completed Phase 1/2 trial assessing safety and efficacy of MoodElite T-4003-1 for improving mood in adults with mild to moderate depressiv…
-
FDA approval · 2023-03-22FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Apotex Corp)
FDA approved a supplemental application for trazodone hydrochloride from Apotex Corp, indicating approval of a generic product under an ANDA…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects [Phase 1]
Phase 1 clinical trial assessing PET imaging of dopaminergic and serotonergic systems in HIV-positive individuals treated for depression; re…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Low Frequency TMS for Depression in Epilepsy [NA]
Clinical trial update reporting completed study on low frequency transcranial magnetic stimulation for depression in epilepsy, with results …
-
FDA approval · 2023-03-20FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the original abbreviated new drug application for clomipramine hydrochloride (generic) by Aurobindo Pharma Limited.
-
FDA approval · 2023-03-15FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for escitalopram oxalate submitted by Exelan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL [NA]
VITAL-DEP reported the completion of the depression endpoint prevention analysis within the VITAL trial and posted the results. The study ev…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression [Phase 2]
Phase 2 study update for Ammoxetine Hydrochloride Enteric-coated Tablets in Major Depressive Disorder is in progress with status currently u…
-
CLINICAL_TRIALS trial_result · 2023-03-02Clinical Trial Update: Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study [Phase 3]
Phase 3 validation study update from CAN-BIND focusing on biomarkers in major depressive disorder.
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse [Phase 3]
Phase 3 trial assessing rapid antisuicidal effects of intranasal ketamine in individuals with comorbid depression and alcohol use disorder c…
-
CLINICAL_TRIALS trial_result · 2023-03-01Clinical Trial Update: The Sub-Saharan Africa Regional Partnership for Mental Health Capacity Building [NA]
Clinical trial update on a Sub-Saharan Africa mental health capacity-building partnership focused on depression; status completed with resul…
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: tDCS for Increasing Exercise Adherence in Depressed Individuals [NA]
A completed clinical trial evaluating transcranial direct current stimulation (tDCS) to increase exercise adherence in individuals with depr…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: A Behavioral Intervention for Depression and Chronic Pain in Primary Care [NA]
A completed clinical trial evaluating a behavioral intervention for depression and chronic pain in primary care; results posted in 2023.
-
FDA approval · 2023-02-17FDA Approved: DOXEPIN HYDROCHLORIDE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's generic doxepin hydrochloride for oral use under an Original Application (ANDA).
-
FDA approval · 2023-02-16FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for escitalopram oxalate from Amneal Pharmaceuticals LLC, confirming approval of their generic produ…
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder [Phase 3]
A Phase 3 long-term comparison of esketamine nasal spray versus quetiapine extended-release, both added to an SSRI/SNRI, in adults with trea…